Appendix 3G
Notification of issue, conversion or payment up of equity & securities. Download...
Read MoreChange in substantial holding
22 December 2020 Form 604 Corporations Act 2001 Section 671B Notice of...
Read MoreCLINUVEL Newsletter VI
Dear shareholders, friends, CLINUVEL’S OUTLOOK The past weeks have seen a flurry...
Read MoreSCIENTIFIC COMMUNIQUÉ VIII
DNA Repair Mechanisms December 2020 Introduction DNA is the repository of genetic...
Read MoreSCENESSE® DNA REPAIR STUDY IN HEALTHY VOLUNTEERS APPROVED
Melbourne, Australia, 30 November 2020 CLINUVEL PHARMACEUTICALS LTD today announced that it...
Read MoreSCIENTIFIC COMMUNIQUÉ VII
The Cerebral Vasculature System in Disease: Atherosclerosis Introduction The human brain is...
Read MoreJefferies Virtual London Healthcare Conference Presentation
20 November 2020 Download presentation & speaker’s notes
Read MoreChair's Letter To Shareholders
19 November 2020 Dear fellow shareholder, I look back at a year...
Read MoreResults of Annual General Meeting
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...
Read MoreMANAGING DIRECTOR’S PRESENTATION TO CLINUVEL ANNUAL GENERAL MEETING
The following is a transcript of the Managing Director’s presentation to the...
Read MoreCHAIR’S ADDRESS TO CLINUVEL ANNUAL GENERAL MEETING
I am up for re-election today, thank you for those who supported...
Read MoreCLINUVEL Strategic Update – Extended
CLINUVEL PHARMACEUTICALS LTD today released a strategic update on its business. An...
Read MoreAPPENDIX 4C AND ACTIVITY REPORT
KEY HIGHLIGHTS: SEPTEMBER QUARTER 2020 • Cash receipts of $12,015,000 • Operating...
Read MoreCLINUVEL Strategic Update – Executive Summary
CLINUVEL PHARMACEUTICALS LTD today released a strategic update on its business. An...
Read More